Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | WRN | Q14191 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910617 | 0.90 | NAAA (0.50) | NAAAALDH1A1DGKAHCAR2DNM1 | |
| SCHEMBL2906907 | 0.88 | NAAA (0.58) | NAAAALDH1A1DGKAHCAR2DNM1 | |
| SCHEMBL2911788 | 0.88 | ALDH1A1 (0.38) | NAAAALDH1A1DGKAPPM1BPTPN1 | |
| SCHEMBL14009796 | 0.87 | NAAA (0.61) | NAAADGKAHCAR2DNM1 | |
| SCHEMBL13248688 | 0.87 | NAAA (0.61) | NAAADGKAHCAR2DNM1 | |
| SCHEMBL2909889 | 0.87 | NAAA (0.61) | NAAADGKAHCAR2DNM1 | |
| SCHEMBL2187425 | 0.86 | ALDH1A1 (0.35) | NAAAALDH1A1DGKAPPM1BPTPN1 | |
| SCHEMBL25145344 | 0.81 | HCAR2 (0.37) | NAAAALDH1A1DGKAPPM1BPTPN1 | |
| SCHEMBL28678358 | 0.81 | GAA (0.41) | ALDH1A1LMNACYP1A2 | |
| SCHEMBL3282607 | 0.81 | NAAA (0.34) | NAAAALDH1A1DGKAPPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385529-A2 | DEVICES FOR CONTROLLED DELIVERY | Femasys, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3787533-B1 | DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230390105-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | POINTILLIST GLOBAL MACRO SERIES OF POINTILLIST PARTNERS LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230329900-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11744729-B2 | Methods and devices for controlled delivery | FEMASYS INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3787533-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | Femasys, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336325-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2019-11-07 | — | — | US | disclosed |
| WO-2018148453-A1 | METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES | FEMASYS, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2219553-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | Valor Medical, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009064698-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | NAAA 1050/4885ALDH1A1 1713/4885DGKA 4011/4885 |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | NAAA 1050/4885ALDH1A1 1713/4885DGKA 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.